Categories
BLOG

cannabis skin cancer

Can Cannabis Treat Skin Cancer?

The potential for new research and treatments in treating diseases is expanding thanks to the global adoption of marijuana for medical use.

As more countries open the doors to the use and investigation of cannabis, medical applications of the drug are set to be expanded as the drug has already showed promise.

Currently the promise outpaces any medically confirmed results or applications for cannabis treating skin cancer patients.

Cannabis experts and market analysts offered valuable insight and 2020 forecasts for the quickly evolving cannabis sector

Read our new report on the MJBizConINT’L Conference

While marijuana and skin cancer have not been effectively paired up for a proper treatment, the cannabis plant may offer more options for patients once more clinical trials and research are confirmed.

While there may be individual cases claiming to credit the drug, cannabis and its derivatives are not being applied for the treatment of skin cancer.

According to the American Cancer Society, skin cancer is the most common type of cancer, accounting for over five million cases per year. This category holds many different variations, however the main three types are basal cell carcinomas, squamous cell carcinomas, and melanomas; the rest are considered rare.

Melanomas develop in specific areas like the neck and face and can be more serious than their counterparts. Basal and squamous cancer cells, on the other hand, are developed based on a person’s sun exposure and mostly develop in the head and neck.

According to the Canadian Cancer Society, treatments of non-melanoma skin cancer include: surgery, radiation therapy, photodynamic therapy and drug therapy including the use of topicals.

Cannabis and cancer could be paired up as more research across the globe begins to take place, looking for new medications and formulations, boosted by the early successes of the drug.

While researching is still lacking in the overall medical marijuana space, serious improvements such as GW Pharmaceuticals (NASDAQ:GWPH) obtaining an approval in the US for its CBD solution treating seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in toddlers.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

After going through its clinical trials, the company’s “Epidiolex” drug approval from the US Food and Drug Administration signalled how top medical agencies were ready to confirm the medical prowess of cannabis and its derivatives for the benefit of patients.

The National Eczema Association vouched for CBD as an option in the treatment of eczema, a skin disease that affects over 30 million people in the US.

“It has long been observed that cannabinoids possess anti-inflammatory, antimicrobial and anti-itch qualities,” The Independent reported.

A study from the the University of Colorado School of Medicine is looking further into the ability of CBD for patients with psoriasis or eczema who have tried using topical steroids or topical immunomodulators.

Robert Dellavalle, professor of dermatology with the University of Colorado, told Inside Science CBD products are growing in popularity but the results are not being collected as properly as it could be.

“I believe it’s a wide-open horizon with tremendous potential that needs to be investigated, but there are a number of regulatory hurdles that need to be overcome and that’s where we are,” he said of his study.

A medical study from the University of Colorado Anschutz Medical Campus showed that the anti-inflammatory sensibilities of cannabinoids are the main reason why they may be a potent agent in combating skin diseases.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

As part of its guide for health care practitioners, Tilray (NASDAQ:TLRY) indicated medical cannabis could aid patients with inflammatory skin diseases such as dermatitis, psoriasis and pruritus.

“And while this research is still relatively formative, the results achieved so far clearly indicate its value and the promising potential of cannabis as effective medicine,” Tilray wrote.

Dave Berg, chief technology officer for software company Strainprint told the Investing News Network the lack of sophisticated research has had an impact on the development of novel therapies for patients using cannabis.

“[I]t’s been very difficult for people to study cannabis in a clinical way, but there’s been a ton observational data… There’s no really strong observational data set that allows us to make proper decisions,” Berg said.

In an effort to raise the research options for cannabis, the Canadian federal government announced it would spend C$10 million over five years to the Mental Health Commission in order to assess the impact of cannabis use on the mental health of Canadians.

The government also promised C$10 million given to the Canadian Centre on Substance Use and Addiction for research purposes.

Skin treatment, either cosmetic or medical has been one of the many sectors revitalized with new cannabis oil products gaining popularity.

These cannabis oil products are developed based on the non psychoactive component of the marijuana plant, cannabidiol (CBD).

Find out what experts say about profiting from the cannabis market in 2020!

Read our FREE 2020 cannabis outlook report!

The introduction of a cosmetics with cannabis elements, supported by Canadian licensed producers is another upcoming element for the skin treatment segment of consumers, and while not medical it does offer more options to the uses of cannabis.

The endorsement from consumers for CBD ointments or other topicals for skin care has been documented with multiple product launched in the fractured US cannabis market.

The increased popularity of these products has led to a rise in the type of claims made by these items in the prevention and upkeep of skin conditions.

A study from the Journal of the American Medical Association found CBD products were often were mislabeled online.

Investor takeaway

In order for skin cancer patients to see the potential benefits from treatments with medical cannabis, a lot still has to change in Canada and abroad.

As the medical and recreational sections of the cannabis space continue drifting apart thanks to legalization efforts, the medical space should obtain more time to properly research and investigate the applications of the drug.

The early position CBD has gained in terms of skin maintenance and treatment could lead to further research on its impact with a more serious disease.

The approval for GW Pharmaceuticals and the increased awareness of the medical benefits for cannabis is moving the needle for how much more research will be put to find out how capable the drug will be in the medical space.

INNdepth

Want more details? Check out these articles for more INNdepth coverage.

Want an overview of investing in cannabis stocks? Check Investing in the Cannabis Industry

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Cannabis experts and market analysts offered valuable insight and 2020 forecasts for the quickly evolving cannabis sector

Read our new report on the MJBizConINT’L Conference

Trulieve Selected and Approved as Medical Cannabis Licensee in West Virginia, Enters 6th State

Leading national cannabis company selected and approved for a processor permit in West Virginia by the Office of Medical Cannabis

Trulieve Cannabis Corp . (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States and the largest cannabis company in Florida announced today that it has been awarded a processor permit by the West Virginia Office of Medical Cannabis. The selection now gives the multi-state operator a presence in six states.

Trulieve’s mission has always been to provide the highest level of cannabis products and customer experience through authentic and reciprocal relationships with its customers and patients. This selection further supports that mission by introducing new patient populations to the Trulieve brand and offering relief they can rely on through the company’s safe, quality products.

“We want to thank the Office of Medical Cannabis for their comprehensive and thoughtful approach during this process, and we look forward to building a positive relationship with the state of West Virginia ,” said Kim Rivers , CEO of Trulieve. “We are truly excited to be entering a sixth state. As a processor, we look forward to bringing our Trulieve brand to West Virginia through wholesale opportunities, partnering with other companies to bring their products to market in the state, and executing on our strategic vision to be the leading customer-focused cannabis brand in the United States , with depth in the markets we choose to operate in. Our plan is to be operational as soon as possible to provide access to the patients in West Virginia .”

Trulieve is committed to investing in the communities it operates in and will further this commitment by working with well-regarded local businesses during construction and operation. Trulieve expects to be operational in the state within the next six months.

About Trulieve

Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also operates in California , Massachusetts , Connecticut and Pennsylvania . Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX Best Market under the symbol TCNNF.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

To learn more about Trulieve, visit www.Trulieve.com .

The Canadian Securities Exchange has not reviewed, approved or disapproved the ‎content of this news release.‎

Forward-Looking Statements
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company and statements with regard to the Report and the Company’s response thereto. Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

SOURCE Trulieve Cannabis Corp.

News Provided by Canada Newswire via QuoteMedia

Can cannabis treat skin cancer? Thanks to a legalization boom across the globe, more companies and researchers think it’s a possibility.